<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Rituximab desensitization</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Rituximab desensitization</h1>
<div class="graphic"><div class="figure"><div class="ttl">Rituximab desensitization</div><div class="cntnt"><table cellspacing="0"><colgroup span="8" width="12%"></colgroup> <tbody> <tr> <td class="highlight_gray_text" colspan="8"><strong>Desensitization protocol instructions:</strong></td> </tr> <tr> <td class="indent1" colspan="8">1. Confirm written consent is in medical record. Initial desensitization is performed in the medical ICU.</td> </tr> <tr> <td class="indent1" colspan="8">2. Please ensure preceding dose of beta blockers was held, unless otherwise advised by supervising physician.</td> </tr> <tr> <td class="indent1" colspan="8">3. Obtain IV access and vital signs (temperature, HR, BP, RR, oxygen saturation, peak flow).</td> </tr> <tr> <td class="indent1" colspan="8">4. Have at bedside: epinephrine 0.3 mg (for adult) for IM injection, peak flow meter, and BP cuff.</td> </tr> <tr> <td class="indent1" colspan="8">5. A nurse must closely observe the patient throughout the protocol (one to one).</td> </tr> <tr> <td colspan="8"><strong>Premedicate</strong> 20 minutes before starting infusion with diphenhydramine (25 mg IV) and famotidine (20 mg IV).</td> </tr> <tr> <td colspan="8"><strong>Administration:</strong> Hang each solution successively, changing the rate every 15 minutes, per protocol. The IV tubing should be pre-flushed with the appropriate solution (1, 2, or 3) and attached at the IV hub, prior to starting infusion with each bag. There is no reason to wait between bags. Vital signs should be taken and recorded every 15 minutes, and every 30 minutes during the last step (step 12).</td> </tr> <tr> <td class="highlight_gray_text" colspan="4"><strong>Name of medication:</strong></td> <td colspan="4"><strong>Rituximab</strong></td> </tr> <tr> <td class="highlight_gray_text" colspan="4"><strong>Target dose (mg)</strong></td> <td colspan="4"><strong>600</strong></td> </tr> <tr> <td class="highlight_gray_text" colspan="4"><strong>Standard volume per bag (mL)</strong></td> <td colspan="4"><strong>250</strong></td> </tr> <tr> <td class="highlight_gray_text" colspan="4"><strong>Final rate of infusion (mL/hour)</strong></td> <td colspan="4"><strong>75</strong></td> </tr> <tr> <td class="sublist1" colspan="8"> </td> </tr> <tr> <td class="highlight_gray_text" colspan="4"><strong>Calculated target concentration (mg/mL)</strong></td> <td colspan="4"><strong>2.4</strong></td> </tr> <tr> <td class="highlight_gray_text" colspan="4"><strong>Standard time of infusion (minutes)</strong></td> <td colspan="4"><strong>200</strong></td> </tr> <tr> <td class="sublist1" colspan="8"> </td> </tr> <tr> <td class="highlight_gray_text" colspan="6"> </td> <td class="highlight_gray_text centered align_middle"><strong>Total mg per bag</strong></td> <td class="highlight_gray_text centered align_middle"><strong>Amount of bag infused (mL)</strong></td> </tr> <tr> <td class="highlight_lght_gray_text" colspan="3"><strong>Solution 1</strong></td> <td>250</td> <td>mL of</td> <td>0.024 mg/mL</td> <td>6.000</td> <td>8.67</td> </tr> <tr> <td class="highlight_lght_gray_text" colspan="3"><strong>Solution 2</strong></td> <td>250</td> <td>mL of</td> <td>0.240 mg/mL</td> <td>60.000</td> <td>17.58</td> </tr> <tr> <td class="highlight_lght_gray_text" colspan="3"><strong>Solution 3</strong></td> <td>250</td> <td>mL of</td> <td><strong>2.382 mg/mL</strong></td> <td>595.573</td> <td>250.00</td> </tr> <tr> <td colspan="8"><strong>PLEASE NOTE:</strong> The total volume and dose dispensed are more than the final dose given to patient because the initial solutions are <em>not completely infused</em></td> </tr> <tr> <td class="highlight_gray_text centered align_middle"><strong>Step</strong></td> <td class="highlight_gray_text centered align_middle"><strong>Solution</strong></td> <td class="highlight_gray_text centered align_middle"><strong>Rate (mL/hour)</strong></td> <td class="highlight_gray_text centered align_middle"><strong>Time (minutes)</strong></td> <td class="highlight_gray_text centered align_middle"><strong>Volume infused per step (mL)</strong></td> <td class="highlight_gray_text centered align_middle"><strong>Dose administered with this step (mg)</strong></td> <td class="highlight_gray_text centered align_middle"><strong>Cumulative dose (mg)</strong></td> <td class="highlight_gray_text centered align_middle"><strong>Fold increase per step</strong></td> </tr> <tr> <td>1</td> <td>1</td> <td>1.9</td> <td>15</td> <td>0.47</td> <td>0.0113</td> <td>0.0113</td> <td>–</td> </tr> <tr> <td>2</td> <td>1</td> <td>4.7</td> <td>15</td> <td>1.17</td> <td>0.0281</td> <td>0.0394</td> <td>2.5</td> </tr> <tr> <td>3</td> <td>1</td> <td>9.4</td> <td>15</td> <td>2.34</td> <td>0.0563</td> <td>0.0956</td> <td>2</td> </tr> <tr> <td>4</td> <td>1</td> <td>18.8</td> <td>15</td> <td>4.69</td> <td>0.1125</td> <td>0.2081</td> <td>2</td> </tr> <tr> <td>5</td> <td>2</td> <td>4.7</td> <td>15</td> <td>1.17</td> <td>0.2813</td> <td>0.4894</td> <td>2.5</td> </tr> <tr> <td>6</td> <td>2</td> <td>9.4</td> <td>15</td> <td>2.34</td> <td>0.5625</td> <td>1.0519</td> <td>2</td> </tr> <tr> <td>7</td> <td>2</td> <td>18.8</td> <td>15</td> <td>4.69</td> <td>1.1250</td> <td>2.1769</td> <td>2</td> </tr> <tr> <td>8</td> <td>2</td> <td>37.5</td> <td>15</td> <td>9.38</td> <td>2.2500</td> <td>4.4269</td> <td>2</td> </tr> <tr> <td>9</td> <td>3</td> <td>9.4</td> <td>15</td> <td>2.34</td> <td>5.5835</td> <td>10.0104</td> <td>2.481554688</td> </tr> <tr> <td>10</td> <td>3</td> <td>18.8</td> <td>15</td> <td>4.69</td> <td>11.1670</td> <td>21.1774</td> <td>2</td> </tr> <tr> <td>11</td> <td>3</td> <td>37.5</td> <td>15</td> <td>9.38</td> <td>22.3340</td> <td>43.5114</td> <td>2</td> </tr> <tr> <td>12</td> <td>3</td> <td><strong>75.0</strong></td> <td>186.875</td> <td>233.59</td> <td>556.4886</td> <td>600.0000</td> <td>2</td> </tr> <tr> <td colspan="8"><strong>Total time: 351.875 minutes = 5.86 hours</strong></td> </tr> <tr> <td class="highlight_gray_text" colspan="8"><strong>Monitoring and charting during desensitization:</strong></td> </tr> <tr> <td class="indent1" colspan="8">Please clearly document any reaction, including:</td> </tr> <tr> <td class="indent2" colspan="8">a. Patient's symptoms, vital signs, and physical findings;</td> </tr> <tr> <td class="indent2" colspan="8">b. Exactly when the reaction occurred (ie, what step, how many minutes into that step);</td> </tr> <tr> <td class="indent2" colspan="8">c. Treatment administered, how and when the reaction resolved, and when the protocol was restarted.</td> </tr> <tr> <td class="highlight_gray_text" colspan="8"><strong>Treatment of allergic reactions:</strong></td> </tr> <tr> <td class="indent1" colspan="8">1. <strong>For mild reactions:</strong> In case of isolated itching, flushing, hives, mild chest tightness, nausea, abdominal pain, or back pain, with normal vital signs, stop the infusion and treat with IV diphenhydramine. Observe patient until the reaction subsides, then resume the protocol at the point where the infusion was stopped.</td> </tr> <tr> <td class="indent1" colspan="8">2. <strong>For severe reactions:</strong> In case of hypotension, throat swelling, wheezing/respiratory distress, or decreased oxygen saturation, stop the infusion and treat with epinephrine 0.3 mg IM × 1, diphenhydramine methylprednisolone IV, oxygen, nebulized albuterol for bronchospasm, and IV fluids (normal saline), per AHA guidelines. Place patient in a recumbent position if hypotensive. Consider glucagon 1 to 2 mg IV bolus if patient has taken beta blockers, followed by infusion at 1 to 5 mg/hour. <strong>Immediately alert the housestaff and supervising physician.</strong> When the patient is stable, the protocol will be resumed as instructed by the supervising physician. <em>Patient should be discharged with prescription for an epinephrine autoinjector.</em></td> </tr> <tr> <td class="indent1" colspan="8"><strong>Contact the supervising physician for ANY severe or prolonged reaction, or any questions regarding the protocol, reactions, and appropriate management.</strong></td> </tr> </tbody></table></div><div class="graphic_footnotes">ICU: intensive care unit; IV: intravenous; HR: heart rate; BP: blood pressure; RR: respiratory rate; IM: intramuscular; AHA: American Heart Association.</div><div class="graphic_reference">Courtesy of Mariana C Castells, MD, PhD.</div><div id="graphicVersion">Graphic 80597 Version 5.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
